Genscript Biotech Corporation announced that Ms. Wang Jiafen had tendered resignation from her positions as a non-executive director and a member of the strategy committee of the Company due to the attainment of statutory retirement age, with effect from 5 July 2024; and Dr. Wang Xuehai had tendered resignation from his position as an independent non-executive Director due to his intention to devote more time to other business commitments, with effect from 5 July 2024. The Board further announces that, with effect from 5 July 2024, Ms. Wang ceased to be a member of the Strategy Committee and Dr. Shi Chenyang, an independent non-executive Director of the Company, has been appointed as a new member of the Strategy Committee.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.42 HKD | -0.96% |
|
+38.46% | -37.46% |
Jul. 10 | Genscript Biotech to Use 68,054 RSA Shares for Scheme, Over 425 Million Shares Available Under General Mandate | MT |
Jul. 09 | Genscript Biotech Grants Restricted Shares Under Incentive Scheme | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.46% | 2.73B | |
+22.15% | 46.55B | |
+45.94% | 41.84B | |
-2.37% | 40.84B | |
+33.84% | 32.95B | |
-6.35% | 28.27B | |
+20.42% | 27.78B | |
+48.83% | 14.26B | |
+45.00% | 13.69B | |
+0.06% | 12.18B |
- Stock Market
- Equities
- 1548 Stock
- News Genscript Biotech Corporation
- Genscript Biotech Corporation Announces Board and Committee Changes